$BNTX (+0,93%) Could BioNTech become one of the top picks for 2025?
If the results of the current studies are confirmed, BioNTech could launch the first cancer therapies on the market in 2026. You can imagine what that means. That would give the share a strong boost🚀
Even though the share price has already moved quite a bit away from the lows in the summer, it is still an interesting level!
Daily chart:
Weekly chart:
BioNTech exhibits "OUTSTANDING" financial health, supported by strong cash flow metrics.
According to BMO Capital, the safety profile of BNT324 is in line with other ADCs currently available on the market. BioNTechs
strong
financial
positionwith more cash than debt and a healthy liquidity ratio of 7.33, provides robust support for its drug development initiatives. In addition, they highlighted that the drug showed promising early efficacy results, particularly in patients with small cell lung cancer (SCLC).
BioNTech's continued Outperform rating reflects confidence in the drug's potential and its alignment with the company's development goals.
I have BioNTech in my portfolio and it is also one of the few individual stocks in my children's portfolios - the time factor plays into their hands anyway 😎🏦
